Tag Archives: IP

Spotlight on India’s Emerging Biotech Sector

india-flag

India’s biotechnology sector is a burgeoning one, with more than 325 companies and some with revenues in the billions of dollars. According to the BioSpectrum-ABLE (Association of Biotechnology Led Enterprises) Biotech Industry Survey of 2011, the industry has grown by 21.5% in 2006-2011, surging to $4 billion. Furthermore, India is the world’s largest manufacturer of vaccines and the growth of India vaccine makers arises from their ability to develop and produce high-quality vaccines with low Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Prior User Rights and Trade Secrets

AA049539

By Joe Allen, President, Allen and Associates One theme of the day is the cloud of uncertainity overhanging the US patent system. This was underscored in the Prior User Rights and Trade Secrets session at the 2012 BIO International Convention as well. The new prior user rights defense which came into effect with enactment of the America Invents Act (AIA) was very differently viewed by the small biotech company perspective given by Mary Ann Dillahunty (Oncolytics Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Measuring the Impact of Innovation

USPTO

By Joe Allen, President, Allen and Associates It’s always an indication of interest and importance in a topic when a panel draws a standing room only crowd. And that was the case with the Measuring the Impacts of Innovation: What is the Future of Tech Transfer? session at the 2012 BIO International Convention. The panel focused on the need to help policy makers, institutions and the public identify appropriate measures for how publicly funded R&D Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech IP Challenges Around the World: BIO’s Special 301 Submission

satellite-image

BIO recently submitted its Special 301 Submission highlighting intellectual property (IP) challenges around the world.  In particular, BIO informed the United States Trade Representative (USTR) of the persistent problems biotech companies face with issues including counterfeiting, large backlogs and patent office inefficiency, differing judicial standards for enforcement, compulsory licensing, inadequate data protection, lack of patentability of biotech inventions, overbearing genetic resources access and benefit regimes, technology transfer issues and a great need for international harmonization Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Brazilian Innovation: A Patent Success

plant

The story of Acheflan highlights the role of patents in homegrown innovation in developing countries.  Professor Michael Ryan of George Washington University Law School reviewed several case studies (including Acheflan) in Brazil that highlight the differences in biomedical innovation both pre- and post-intellectual property reforms. In the early 1980’s, Ache Laboratorios Farmaceuticos (a Brazilian generics manufacturer) became aware of a plant that grew near coastal cities that local fishermen would mash into an oil rub Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,